Taysha Gene Therapies ( NASDAQ: TSHA ) on Wednesday announced the pricing of an underwritten public offering of 14.36M shares of its common stock at a price to the public of $2.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18.
97M shares of its common stock at an offering price of $2.249 per pre-funded warrant. TSHA -11.
15% premarket to $2.19. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering at the public offering price, less the underwriting discount.
The gross proceeds from the offering to Taysha are expected to be about $75 million. The offering is expected to close on or about June 27. Source: Press Release More on Taysha Gene Therapies Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky Taysha Gene Therapies stock slides after commence securities offering to raise $75 million Seeking Alpha’s Quant Rating on Taysha Gene Therapies.
